Psychobiotic Strategies for Managing Anxiety, Depression, and Schizophrenia: A Narrative Review

The gut microbiome exerts significant influence over mental health through the bidirectional communication network of the gut-brain axis. Growing evidence implicates disruptions in gut microbial composition in the pathophysiology of a range of neuropsychiatric conditions, including anxiety, major depressive disorder (MDD), and schizophrenia. Psychobiotics have emerged as a promising adjunctive strategy for modulating mental health outcomes through several interconnected mechanisms, including neurotransmitter modulation, immune regulation, short-chain fatty acid production, and hypothalamic-pituitary-adrenal axis stabilization, among others. This narrative review, intended for clinicians and researchers in integrative and functional medicine, synthesizes current clinical and translational evidence for probiotic interventions across anxiety, MDD, bipolar disorder, and schizophrenia, highlighting key strains, mechanisms, and outcomes. Findings demonstrate that specific Lactobacillus and Bifidobacterium strains show measurable benefit in reducing anxiety and depressive symptom severity, while emerging evidence suggests potential utility in psychotic disorders. Limitations include significant heterogeneity in strain selection, dosing protocols, study populations, and outcome measures, which constrain clinical translation. Future research should prioritize standardized protocols, longitudinal designs, and functional microbiome profiling to support personalized, microbiome-informed approaches to mental health care.